Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The product of SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. Additionally we are shipping Synovial Sarcoma, X Breakpoint 2 Proteins (6) and many more products for this protein.
Showing 10 out of 63 products:
Human Polyclonal SSX2 Primary Antibody for WB - ABIN2780224
Fernebro, Francis, Edén, Borg, Panagopoulos, Mertens, Vallon-Christersson, Akerman, Rydholm, Bauer, Mandahl, Nilbert: Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. in International journal of cancer. Journal international du cancer 2005
Show all 2 references for ABIN2780224
Human Monoclonal SSX2 Primary Antibody for IHC (p), ELISA - ABIN520520
Smith, Cronk, Lang, McNeel: Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. in Cancer research 2011
Show all 2 references for ABIN520520
results reveal two important phenotypes of ectopic SSX2 expression that may drive/support tumorigenesis: First, immediate induction of genomic instability, and second, long-term support of tumor cell growth.
The tumor-specific pattern of expression of SSX2.
primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 (show CTAG1B Antibodies) are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation
SS18 (show SS18 Antibodies)-SSX-induced Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression.
SSX2, SSX3 (show SSX3 Antibodies), and SSX4 (show SSX4 Antibodies) are expressed in the lung tissue of only 3.5% early-stage non-small cell lung cancer patients.
These results suggest that the characteristic speckle localization pattern of SS18 (show SS18 Antibodies)-SSX is strongly involved in the tumorigenesis through the SSX moiety of the SS18 (show SS18 Antibodies)-SSX fusion protein.
the initial events that likely occur when SYT (show SS18 Antibodies)-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation
The regulation of estrogen receptor alpha (show ESR1 Antibodies) signaling by target proteins of SSX2 may explain the metastatic potential of breast cancer cells.
The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase (show RAB40C Antibodies) interactor, RABIN3 (show RAB3IP Antibodies), and a novel nuclear protein (show RDBP Antibodies), SSX2IP (show SSX2IP Antibodies).
existence of fusion with SYT (show SS18 Antibodies) in synovial sarcoma
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X\\\\;18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.
cancer/testis antigen 5.2
, cancer/testis antigen family 5, member 2a
, protein SSX2
, sarcoma, synovial, X-chromosome-related 2
, synovial sarcoma, X breakpoint 2B
, tumor antigen HOM-MEL-40
, cancer/testis antigen family 5, member 2b
, synovial sarcoma, X breakpoint 2
, synovial sarcoma, X breakpoint 3